OrthoSpace

Company Overview

Snapshot

Founded in March 2009, OrthoSpace operated with 11–50 employees, developing medical devices for the orthopedic market. The company was acquired by Stryker Corporation in March 2019.

Business overview

OrthoSpace develops and commercializes simple-to-implant biodegradable balloon systems for the orthopedic market. Its core product, InSpace, is designed to alleviate pain and improve range of motion for patients with irreparable rotator cuff tears through a minimally invasive procedure. The company serves the healthcare industry, focusing on patients and providers, and operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In March 2019, OrthoSpace was acquired by Stryker Corporation for $220 million. This acquisition by a major medical technology company validates OrthoSpace's innovative biodegradable balloon system technology and signals a successful exit for its investors, integrating its solution into a broader orthopedic portfolio.

Company Intelligence Q&A

What is OrthoSpace's primary product?

OrthoSpace's primary product is InSpace, a biodegradable balloon system designed for the treatment of irreparable rotator cuff tears. It aims to reduce pain and improve range of motion through a minimally invasive procedure.

When was OrthoSpace acquired and by whom?

OrthoSpace was acquired by Stryker Corporation in March 2019.

What was the reported acquisition amount for OrthoSpace?

OrthoSpace was acquired by Stryker Corporation in March 2019 for $220 million, as reported by Globes.

Which investors participated in OrthoSpace's December 2016 funding round?

In December 2016, OrthoSpace received funding from Triventures and HealthpointCapital.

What was a key development for OrthoSpace's InSpace product in March 2018?

In March 2018, OrthoSpace completed enrollment for its InSpace™ U.S. Pivotal Study, a significant step towards regulatory approval in the United States.